Results of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show that the Classical Pathway is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis

Results of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show that the Classical Pathway is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis - Annexon Biosciences